Symbiotec Pharmalab Ltd IPO
- Price band
- ₹938 to ₹988
- Issue size
- ₹1,757 Cr
- Issue price
- ₹988
- Lot size
- 15 shares
- Listing return
- 0%
Listed ₹988
Opens
24 Aug 2026
Closes
27 Aug 2026
Allotment
28 Aug 2026
Listing
1 Sep 2026
Subscription
About the company
Symbiotec Pharmalab is a pharmaceutical and biotechnology firm that develops and manufactures active pharmaceutical ingredients (APIs), biotech products, and complex injectables. It works across three platforms: organic chemistry, biotechnology, and complex injectables. The company offers more than 60 corticosteroid and steroid hormone APIs, such as hydrocortisones, betamethasone, methylprednisolones, progesterones, estrogens, and testosterone. It also provides contract development and manufacturing organisation (CDMO) services to pharmaceutical and nutraceutical companies.
As of March 31, 2026, Symbiotec had two operational API plants in Rau and Pithampur, Madhya Pradesh. It has also commissioned a biomanufacturing facility in Ujjain and a complex injectables facility in Mhow, Madhya Pradesh. The company runs three R&D centres in Indore, each focused on organic chemistry, biotechnology, or complex injectables. Its products and services have reached over 200 customers in more than 40 countries.
Objective of IPO proceeds
| Particulars | Estimated amount (₹ Cr.) |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company | 112.5 |
| General corporate purposes | — |
Key performance indicators (KPIs)
for the fiscal year ended March 31, 2026
- ROE11.19%
- ROCE11.56%
- EBITDA Margin26.59%
- PAT Margin12.6%
- Return on Net Worth (RoNW)9.48%
Net Asset Value (NAV) per Equity Share
184.69
EPS (Pre-IPO)
19.1
View table
| KPI | Value (for the fiscal year ended March 31, 2026) |
|---|---|
| ROE (%) | 11.19 |
| ROCE (%) | 11.56 |
| EBITDA Margin (%) | 26.59 |
| PAT Margin (%) | 12.6 |
| Return on Net Worth (RoNW) (%) | 9.48 |
| Net Asset Value (NAV) per Equity Share (₹) | 184.69 |
| EPS (Pre-IPO) (₹) | 19.1 |
Financials
₹ croreRevenue
869.15
Total Assets
1,780.79
Profit
109.9
View table
| Line | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 716.25 | 751.55 | 869.15 |
| Total Assets | 1,294.78 | 1,579.65 | 1,780.79 |
| Profit | 100.05 | 96.78 | 109.9 |
Book running lead managers & registrar
| Book running lead managers | JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory, Securities (India) Private Limited |
|---|---|
| Registrar to the issue | MUFG Intime India Private Limited |
Symbiotec Pharmalab IPO contact details
| Company name | Symbiotec Pharmalab Limited |
|---|---|
| Registered office | 385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India |
| Phone | +91 731 667 6405 |
| secretarial@symbiotec.com | |
| Website | www.symbiotec.com |
Symbiotec Pharmalab IPO registrar contact details
| Company name | MUFG Intime India Private Limited |
|---|---|
| Phone | +91 810 811 4949 |
| symbiotecpharmalab.ipo@in.mpms.mufg.com | |
| Website | in.mpms.mufg.com/ |
Thesis
- 1
In FY26, the company held a global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal-hormone APIs (excluding androstenedione and hydroxyprogesterone caproate), with product-specific shares of 80.1% in hydrocortisone, 76.4% in testosterone, and 76.0% in methylprednisolone.
- 2
Its portfolio of over 60 corticosteroid and steroidal-hormone APIs, in sterile and non-sterile forms, covered about 90% of such API products as of March 31, 2026, and included 43 drug master files with the US FDA and 23 certificates of suitability from the EDQM.
- 3
The company serves both domestic and international markets, with exports contributing Rs 582.64 crore, Rs 414.78 crore, and Rs 429.52 crore in FY26, FY25, and FY24, or 67.04%, 55.19%, and 59.97% of revenue from operations; as of March 31, 2026, it had over 200 customers across more than 40 countries, including more than 50 domestic and over 150 export customers.
- 4
Its vertically integrated, multi-scale manufacturing platform had, as of March 31, 2026, a maximum chemical synthesis capacity of 584.67 MT, fermentation capacity of 700 KL, and complex injectable capacity of 20 million vials; backward integration lets it produce key starting materials for products that account for over 80% of revenue, lowering reliance on external intermediates.
- 5
The Rau and Pithampur facilities hold approvals from regulators including the US FDA, EU-GMP, and WHO-GMP.
- 6
R&D spans organic chemistry, biotechnology, and complex injectables through three dedicated centres in Indore as of March 31, 2026; R&D spending was Rs 29.69 crore, Rs 31.14 crore, and Rs 20.51 crore in FY26, FY25, and FY24, equal to 3.42%, 4.14%, and 2.86% of revenue from operations.
- 7
Revenue from operations has grown from Rs 716.25 crore in FY24 to Rs 751.55 crore in FY25 and Rs 869.15 crore in FY26.
Application details
Regular
₹938 - ₹988 · Upto ₹2 Lakhs
15sharesEmployee
₹848 - ₹898 · Upto ₹5 Lakhs
₹90 discount
15sharesHigh Networth Individual
₹938 - ₹988 · ₹2 - ₹5 Lakhs
15sharesMin 210
Figures come from the company filing. This is not a recommendation.